SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Incyte's logo on its building in Delaware
Deals
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
April 23, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Boehringer Ingelheim's office in California
Business
Boehringer, Ochre Bio Team in Potential $1B Deal to Develop Regenerative Liver Drugs
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
April 22, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: GSK's headquarters in London
Drug Development
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data
GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up.
April 17, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Novartis' office building in Marburg, Germany
Drug Development
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review
Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in IgA nephropathy patients.
April 16, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Roche Diagnostics building in California
Drug Development
Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
April 15, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna Halts Plans for Kenyan mRNA Vaccine Plant After Taking $1B Financial Hit
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
April 11, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Photo illustration of hundred dollar bill and graph
Business
Nvelop and Seaport Raise $100M in Rounds, Tap Bluebird and Karuna Execs
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
April 9, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Nasdaq signage and building in New York City
Deals
Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
April 5, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Facade of the FDA's office in Maryland
FDA
Basilea Wins FDA Approval for Antibiotic Ending 15-Year Regulatory Quest
Basilea Pharmaceutica received FDA approval for its antibiotic Zevtera in three indications Wednesday, finally getting the drug across the finish line a decade and a half after the agency rejected an earlier submission.
April 4, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Person undergoing an eye exam
Drug Development
Roivant Posts Phase II Eye Disease Win for TYK2 Drug, Plans Pivotal Program
Roivant has chalked up a mid-stage victory for its Pfizer-partnered dual TYK2/JAK1 inhibitor, setting it up to start a Phase III trial in non-anterior non-infectious uveitis this year.
April 2, 2024
 · 
2 min read
 · 
Nick Paul Taylor
External view of AstraZeneca's production plant in Sweden
FDA
AstraZeneca Gets FDA Approval in Boost to Rare Disease Franchise
AstraZeneca has secured the FDA’s green light for Voydeya, a first-in-class, oral, Factor D inhibitor developed as an add-on to its standard-of-care Ultomiris or Soliris for certain patients with paroxysmal nocturnal haemoglobinuria.
April 1, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Close-up of a skin lesion in a patient w
Deals
Avalo Snags Former Eli Lilly Asset and $185M in Major Pipeline Pivot
Avalo Therapeutics rolled the dice on a big pivot Wednesday, acquiring AlmataBio and focusing on the biotech’s ex-Eli Lilly hidradenitis suppurativa candidate over its existing assets.
March 29, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Gene therapy illustration showing an inj
Drug Development
Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint
Nanoscope Therapeutics nabbed a victory on the changed primary endpoint of its Phase IIb vision loss gene therapy trial Tuesday, teeing the biotech up to file for FDA approval of the candidate this year.
March 27, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Healthcare worker holding up a vial for an LDL-C test
FDA
Esperion Targets Seven-Fold Jump in Cholesterol Drug Population with FDA Label Expansion
Esperion bagged broader-than-expected FDA labels for its cholesterol-busting drugs Friday, allowing the biotech to target seven times as many people in the U.S. compared to the old labels.
March 25, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Bayer's global pharmaceuticals headquarters in Germany
Business
Bayer’s Prostate Cancer Drug Nubeqa on Track to Generate Blockbuster Sales in 2024
At Thursday’s Pharma Media Day, Bayer touted Nubeqa as the fastest growing androgen receptor inhibitor in the U.S., which will achieve blockbuster status this year.
March 22, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More